Born: Milan, April 2, 1926
A.:c/o IFOM, Via Adamello 16, I-20139 Milano
tel.: (+39) 02574303200
Educ.:1950, degree in medicine and surgery, Univ. of Milan; 1960, teaching qualification in anatomy and pathological histology; 1966, in experimental oncology
Car.:1951-55, worked at the Anatomical Pathology Institute, Univ. of Milan; 1956-60, associate researcher in chemical cancerogenesis, Experimental Oncology and Diagnostic Histopathology Divisions, Chicago Medical School (USA); his acquaintance with Pietro Buccalossi and Umberto Veronesi was fundamental in the establishment of the ACRO project (growth control of neoplasms), the Associazione Italiana per la Ricerca sul Cancro - AIRC (Italian Association for Cancer Research), Istituto Nazionale Tumori - INT (National Cancer Institute) and IFOM - FIRC Institute of Molecular Oncology (research centre on molecular oncology); 1961-70, head Experimental Carcinogenesis Section, INT; 1966-70, chmn. UICC Committee on Carcinogenesis; 1968, appointed board mem. SAES Getters S.p.A.; 1971-91, dir. Experimental Oncology Division, INT; 1979-83, pres. European Association for Cancer Research; 1980-82, pres. Immunology Cooperation Group; 1980-83, mem. scientific board International Agency for Research on Cancer, Lyon; 1985-91, deputy scientific dir. INT; 1992-2000, scientific dir. AIRC; 1994-2011, research coordinator European Institute of Oncology, Milan; 2001-07, board mem. Istituto Superiore di Sanità (Higher Institute of Health), Rome; at present, pres. IFOM - FIRC Institute of Molecular Oncology, Milan; vice-pres. Fondazione Italiana per la Ricerca sul Cancro - FIRC (Italian Foundation for Cancer Research) and AIRC; board mem. SAES Getters S.p.A.
Publs.: over 180 articles on various issues of experimental oncology, including experimental studies on chemical carcinogenesis, leukemogenesis, viral immunology and molecular biology of experimental and human tumours. See Survey: IFOM - FIRC Institute of Molecular Oncology
President FIRC-AIRC and Vice-President IFOM
He has a degree in Humanities from the University of Lyon. He joined Milan-based Pirelli SpA in 1962 and served management positions in Italy, in the USA and in Brazil.
Mr. Sierra served as Chief Executive Officer of Pirelli SpA from 1991 to 1995 and is currently Special Advisor for the administration of Pirelli's international companies.
From 2005 he is president of AIRC and FIRC. He has a passion for photography, has taken part to exhibitions and has published several books in this artistic field.
Prof. Foiani has a Ph.D. in Molecular Biology from the University of Milan (Italy).
Since 2002, Prof. Foiani, who is also Head of the Genome Integrity Laboratory at IFOM since its establishment, is Full Professor in Molecular Biology at the University of Milan.
His research interest focuses on the regulatory mechanisms that control genome integrity. Particularly, his work has contributed to elucidate the cellular mechanisms causing genome instability in cancer cells and chromosome abnormalities in certain human syndromes leading to cancer predisposition. Prof. Foiani has more than 80 papers published in international scientific journals.
Since 2008 Prof. Marco Foiani is the Scientific Director of IFOM.
Prof. Foiani was honored with internationally recognized memberships and awards, such as: the European Molecular Biology Organization membership; the Academia Europaea membership; the New York Academy of Sciences membership; the Italian Society of Genetics (AGI) membership; the Italian Society of Biophisics and Molecular Biology (SIBBM) membership; the Award from the Italian Society for Biophysics and Molecular Biology (SIBBM); the Biotec Award promoted by Amgen and Dompé; the "Chiara D'Onofrio" Prize from the Italian Federation of Life Sciences.
He was the founder in 2009 of the European Nanomedicine Foundation (CEN) and vice-president up to 2011.
also member of the Scientific Advisory Board of AIRC, the Italian Cancer Research Association, member of the editorial board of Cell and editor and reviewer for top impact factor scientific journals.
Francesco Blasi born in Naples, October 19, 1937.
MD from Naples University Medical School, then two post-Docs at the Max Planck Institut fuer Biophysik (Frankfurt, Germany) and NIH (National Institute of Arthritis and Metabolic Diseases) Bethesda, MD (U.S.A.).
In 1970 back in Italy at the CNR Research Center in the Naples University Medical School, then in 1980 Full Professor at the II Faculty of Medicine of the University of Naples.
Subsequently, Professor at the University of Copenhagen, Denmark and finally in Milano since 1992
. Is at IFOM since 2004, Director of research program Transcriptional Regulation in Development and Cancer.
From 2007 to 2011 coordinates the Molecular Oncology PhD program of SEMM. In 2011 becomes Deputy Director for Science of IFOM.
Has previously been Director of the International Institute of Genetics and Biophysics of CNR in Naples (1980-1983), of the Molecular and Cellular Biology Center in Copenhagen (Denmark), (1988- 1992), and of the Department of Cellular Biology and Functional Genomics (1998-2006) at DIBIT, Ospedale San Raffaele.
In 1979 is elected member of EMBO, the prestigious European Molecular Biology Organization, and 1991-1993 of its Council. Since 1992 is a member of Academia Europaea.
Has received national and international prizes and is Author of over 270 research articles in prestigious international Journals, including Nature and Cell.
Has been a member of the Advisory Board of AIRC, Associazione Italiana per la Ricerca sul Cancro, and of the Board of EMBO Journal.
Giuseppe Della Porta
After studying biochemistry at the University of Bayreuth, Ralf Adams started his research career at the Max-Planck-Institute for Brain Research and the Goethe University Frankfurt in Germany, where he obtained his Ph.D. in 1996. His work involved the cloning of new members of the semaphorin gene family and the characterization of their function in axon guidance.
Next, he moved to Rüdiger Klein's laboratory at the European Molecular Biology Laboratory in Heidelberg and began to work on the role of Eph/ephrin molecules in blood vessel morphogenesis. Together with his collaborator Angel Nebrada, he also investigated the function of the p38alpha mitogen-activated protein kinase.
In 2000, he became head of the Vascular Development Laboratory at the Cancer Research UK London Research Institute (formerly, Imperial Cancer Research Fund), where he and his laboratory made significant achievements by combining genetic approaches in the mouse with a wide range of cell and molecular biology methods. Several of their discoveries are directly relevant for human pathologies. For example, they were the first to show that the Eph receptor ligand ephrin-B1 controls skeletal morphogenesis and that defects in the human gene (EFNB1) lead to Craniofrontonasal Syndrome (CFNS). A different project has connected the cytoplasmic multi-PDZ domain protein GRIP1, an interaction partner of Eph/ephrin proteins and other molecules, with the rare but severe human congenital disease Fraser Syndrome. They also demonstrated that Junctional Adhesion Molecules (JAMs) are critical regulators of cell polarity.
Since he has moved as Director to the Max Planck Institute for Molecular Biomedicine and Professor the University of Münster in 2008, Ralf Adams and his group have continued to provide insight into key processes controlling developmental blood vessel growth and, in particular, its regulation by Notch, VEGF and Eph/ephrin signaling.
Julian Downward obtained his bachelor's degree in Natural Sciences from Cambridge University and then studied for his Ph.D. in the laboratory of Michael Waterfield at the Imperial Cancer Research Fund in London, where he established in 1984 the link between a retroviral oncogene (v-erbB) and a cellular growth regulatory protein, the EGF receptor.
In 1986, he moved to Robert Weinberg's laboratory at the Whitehead Institute at the Massachusetts Institute of Technology in Cambridge, MA, where he began work on the role of Ras proteins in human cancer.
In 1989 he started his own lab at the Imperial Cancer Research Fund, now Cancer Research UK London Research Institute, where his lab has provided insights into the molecular mechanisms of function and regulation of oncogenic proteins of the Ras family and the importance of their mutational activation in human tumours.
In 2005 Julian was made a Fellow of the Royal Society, the UK's national academy of sciences, and became Associate Director of the Cancer Research UK London Research Institute.
Jan Hoeijmakers studied biology in Nijmegen. His PhD work on trypanosomes at the Univ. of Amsterdam resolved the molecular basis for antigenic variation by which trypanosomes switch each time surface coats and thereby escape from immune surveillance causing sleeping sickness.
In 1981 he joined the Dept. of Genetics of the Erasmus Univ. to work on DNA repair. He cloned the first of many subsequent human DNA-repair genes allowing elucidation of the reaction mechanism of nucleotide excision repair, discovered the strong evolutionary conservation of DNA repair, elucidated the basis of several enigmatic human repair syndromes, identified a new class of 'basal transcription disorders', generated a large number of DNA-repair mouse mutants that provided valuable insight into the complex etiology of human repair disorders and discovered a very strong, unanticipated link between DNA damage, repair and aging. Some of the repair mutants exhibit dramatically accelerated but bona fide aging limiting lifespan to only 3 weeks. Conditional mutants allowed targeting of accelerated aging to specific organs/stages of development (e.g. mouse mutants with dramatic aging only in the brain), making aging amenable to manipulation. Expression profiling revealed an unexpected similarity between short- and long-lived mice: both suppress the somatotrophic axis. This work led to the identification of a very important 'survival response' that promotes successful aging and counteracts cancer by redirecting energy from growth to defenses.
A new line of research explores the dynamic organization of DNA repair in living cells and intact organisms. His group generated the first mouse mutants with intrinsic defects in the biological clock. He owns several patents and discovered compounds that influence aging. His multi-disciplinary research has received several important awards.
In 2004 he started the 'DNage' whose mission is to provide solutions for medical/health problems associated with aging.
Dr Ish-Horowicz gained his PhD at the MRC Laboratory of Molecular Biology in Cambridge on tRNA structure, and conducted postdoctoral work on Drosophila molecular genetics with Walter Gehring at the Biozentrum in Basel, Switzerland. He then established his own lab at the Imperial Cancer Research Fund (now Cancer Research UK), initially at their Mill Hill site, then in Oxford and, finally, at the main ICRF/CR-UK Lincoln's Inn Fields laboratory in London. He is currently a Professor of Cell and Developmental Biology at University College London and a Visiting Scientist in the Biochemistry Department, Oxford University.
Dr Ish-Horowicz's studies has driven major advances in understanding the molecular processes that generate different cell-types in developing animals, in both Drosophila and vertebrate model systems. His work identified the first metazoan corepressor, Groucho/TLE, which regulates transcription in response to many signalling pathways, including Notch and Wnt. He also showed how molecular motors transport selected mRNAs along microtubules to help target asymmetric protein production within cells. In vertebrates, he demonstrated that Notch intercellular signalling acts in the nervous system to maintain neuronal stem cells and, thereby, to generate neuronal diversity. He also provided the first evidence that a cyclic transcriptional oscillator acts during vertebrate segmentation in order to produce regular reiterated body-structures such as the axial skeleton. For these and other findings, he was awarded the 1997 Gulbenkian Science Prize and the 2007 Waddington Medal of the British Society of Developmental Biology, and was elected a Fellow of the Royal Society in 2002.
Professor Gordon McVie is widely regarded as a leading international authority in the research and treatment of cancer. Having qualified in the nineteen sixties in science and medicine at Edinburgh University, he was appointed Foundation Senior Lecturer at the Cancer Research Campaign oncology unit at the University of Glasgow in 1975. He trained in the US, and spent sabbaticals in Paris, Sydney and Amsterdam.
He is currently Clinical Research Adviser to the FIRC Institute of Molecular Oncology (IFOM), and is founding editor of ecancer.org, ecancerpatient.org and ecancerLatinoAmerica- online Open Access free websites. Recently he was Senior Consultant to the European Institute of Oncology, Milan. He is visiting professor at Cancer Studies, Kings College London.
Previously Professor McVie was Chief Executive of the Cancer Research Campaign (CRC), which, under his aegis, took over seventy molecules from the lab into clinical trial. He led CRC into a merger with Imperial Cancer Research Fund which formed Cancer Research UK, in 2002, and was joint CEO with Sir Paul Nurse.
Throughout the Eighties, he was Clinical Research Director at the National Cancer Institute of the Netherlands. As President of EORTC, he set up the present Drug Development Group in Brussels, and with NCI support, the European New Drug Development Network. He followed Sir Walter Bodmer as Chair of the UICC Fellowships Programme in 1990 and held the post for eight years.
In the UK he was one of the architects of the Cancer Trials Networks in Scotland, Wales, and England, and was a founding member of the National Cancer Research Institute.
Professor McVie is the recipient of numerous awards and has honorary doctorates in science from six universities. He has served on key committees of AACR and ASCO, and on the boards of the National Cancer Institutes of France, Italy, and Holland. He has authored 360 peer-reviewed articles, and contributed to over 35 books.
His commitment to drug discovery and delivery is evidenced by approximately 240 patents granted to CRC scientists under his leadership, several drugs registered including carboplatin, temozolomide and abiraterone and the foundation of 10 biotechnology companies based on CRC intellectual property. His clinical interests, apart from new drug discovery and chemoprevention, are in the management of cancers of the lung, ovary, liver, breast and brain. He is a nonexecutive director of a Danish start-up company, Nanovi. He is a partner with ecancer in 3 FP7 projects from the European Union and a recently awarded Horizon 2020 project.
He was elected as Fellow of the European Association for Cancer Science in 2014, and has been chairman of the European Alliance for Personalised Medicine since early 2016.
He lives in Bristol, UK, with his wife Claudia who is Chief Executive of the cancer charity Tenovus Cancer Care.
Klaus Rajewsky developed a general method of targeted mutagenesis in mouse embryonic stem cells by introducing bacteriophage- and yeast-derived recombination systems, which opened the way for conditional gene targeting. Using this and other methods in his immunological work, he developed, together with N. A. Mitchison and N. K. Jerne, the antigen-bridge model of T-B cell cooperation, identified germinal centers as the sites of antibody somatic hypermutation, the B cell antigen receptor as a survival determinant of B cells, and the germinal center as a major site of human B cell lymphomagenesis, including Hodgkin lymphoma. Over the last years the work of his group has focused on mechanisms of microRNA control and the development of mouse models of human B cell lymphomas.
After postdoctoral work at the Institut Pasteur in Paris he built an immunology department at the Institute for Genetics at the University of Cologne, where he stayed for 38 years, was the founding Program Coordinator of the EMBL Mouse Biology Program at Monterotondo near Rome, worked for 10 years at Harvard Medical School in Boston, and is since 2012 at the Max-Delbrück-Center for Molecular Medicine in Berlin, Germany.
Klaus Rajewsky won numerous scientific awards and is a member of several learned societies including the National Academy of Sciences of the USA and the American Academy of Arts and Sciences.
K. (Vijay) Vijay Raghavan’s research aims to understand motor- and olfactory-circuit assembly: from deciphering how each component is made, interacts, and stabilizes to functioning in the animal to allowing behavior for in the real world. Related to the development of network function in the maintenance in the mature animal; another aspect of the work in the laboratory addresses how mature neurons and muscles are maintained. The laboratory uses a genetic approach, mainly using the fruit fly but also collaborating with those using mouse and cell-culture.
VijayRaghavan is Distinguished Professor of the National Centre for Biological Sciences (NCBS) of the Tata Institute of Fundamental Research (TIFR) in Bangalore, India and, since January 28, 2013, Secretary of the Department of Biotechnology Government of India. Before VijayRaghavan was the Director of NCBS and the interim head of InStem, a new institute being nurtured by NCBS. He continues to be active in research with his research laboratory at the NCBS in Bangalore.
He studied engineering at the Indian Institute of Technology, Kanpur. His doctoral work was at TIFR, Mumbai (Bombay University) and postdoctoral work at the California Institute of Technology.
VijayRaghavan was a member of the Science Advisory Council to the Prime Minister of India, Associate Member of the EMBO, Fellow of the Indian Academies of Sciences and a Fellow of the Royal Society. He is a JC Bose fellow of the Government of India